Core Viewpoint - Xinde New Materials (301349.SZ) reported an increase in institutional and foreign investment holdings in its third-quarter report for 2025, indicating growing confidence from investors in the company's performance and prospects [1][2]. Group 1: Institutional Holdings - As of October 26, 2025, a total of 9 institutional investors disclosed holdings in Xinde New Materials A-shares, with a combined holding of 15.03 million shares, representing 15.03% of the total share capital [1]. - The institutional holding ratio increased by 1.15 percentage points compared to the previous quarter [1]. - Notable institutional investors include Liaoyang Xinde Enterprise Management Consulting Center (Limited Partnership), Goldman Sachs, UBS AG, and CITIC Securities Asset Management (Hong Kong) [1]. Group 2: Public Fund Holdings - In the current period, 53 public funds were disclosed, including Anxin Consumption Medicine Stock A, Anxin New Growth Mixed A, and Southern Junxin Flexible Allocation Mixed A, which were not reported in the previous quarter [1]. Group 3: Foreign Investment - One foreign fund, UBS AG, increased its holdings by 0.15% compared to the previous period [2]. - Three new foreign institutions disclosed their holdings, including Goldman Sachs, CITIC Securities Asset Management (Hong Kong), and Barclays Bank PLC [2].

Group 1 - The core point of the news is that Ruoyuchen's stock price has been declining for six consecutive days, with a total drop of 14.73% during this period, currently trading at 41.03 CNY per share and a market capitalization of 12.763 billion CNY [1] - Ruoyuchen Technology Co., Ltd. was established on May 10, 2011, and went public on September 25, 2020. The company is based in Guangzhou, Guangdong Province, and its main business includes online agency operations, channel distribution, and brand planning [1] - The revenue composition of Ruoyuchen's main business includes 45.75% from self-owned brands, 28.83% from agency operations, and 25.42% from brand management [1] Group 2 - According to data, a fund under Anxin Fund has heavily invested in Ruoyuchen, specifically the Anxin Consumer Medicine Stock A fund, which increased its holdings by 7,420 shares in the second quarter, now holding 182,800 shares, accounting for 5.29% of the fund's net value [2] - The Anxin Consumer Medicine Stock A fund has a total scale of 206 million CNY and has achieved a return of 29.71% this year, ranking 1548 out of 4218 in its category [2] - The fund managers, Chen Songkun and Xu Yanpeng, have had varying performance during their tenure, with Chen achieving a best return of 28.13% and Xu also achieving the same best return during their respective management periods [2]

Group 1 - The core point of the article highlights the recent performance of Ruoyuchen Technology Co., Ltd., which saw a 5.1% increase in stock price, reaching 44.90 CNY per share, with a trading volume of 276 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 13.967 billion CNY [1] - Ruoyuchen Technology, established on May 10, 2011, and listed on September 25, 2020, is based in Guangzhou, Guangdong Province. The company specializes in online agency operations, channel distribution, and brand planning, offering services such as brand positioning, store operations, channel distribution, integrated marketing, data mining, and supply chain management [1] - The revenue composition of Ruoyuchen Technology includes 45.75% from its own brands, 28.83% from agency operations, and 25.42% from brand management [1] Group 2 - From the perspective of major fund holdings, data indicates that a fund under Anxin Fund has heavily invested in Ruoyuchen. Anxin Consumer Medicine Stock A (000974) increased its holdings by 7,420 shares in the second quarter, totaling 182,800 shares, which accounts for 5.29% of the fund's net value, making it the third-largest holding [2] - Anxin Consumer Medicine Stock A (000974) was established on March 19, 2015, with a latest scale of 206 million CNY. Year-to-date returns stand at 38.95%, ranking 1437 out of 4220 in its category, while the one-year return is 39.06%, ranking 1365 out of 3852. Since inception, the fund has achieved a return of 57.27% [2] - The fund managers, Chen Songkun and Xu Yanpeng, have tenures of 4 years and 3 years respectively, with total assets under management of 209 million CNY and 229 million CNY. Their best and worst fund returns during their tenures are 36.72% and -32.57% for Chen, and 41.4% and 10.04% for Xu [2]